# A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)

> **NCT02774278** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 264 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT02774278
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2016-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02774278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02774278, "A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02774278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*